Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
14 EUR | -0.85% | +1.60% | +42.57% |
Apr. 11 | Morgan Stanley Adjusts Price Target on Abivax to $16 From $15, Maintains Equalweight Rating | MT |
Apr. 08 | Transcript : ABIVAX Société Anonyme, 2023 Earnings Call, Apr 08, 2024 |
Sales 2024 * | 2.62M 2.79M | Sales 2025 * | 2.11M 2.25M | Capitalization | 888M 947M |
---|---|---|---|---|---|
Net income 2024 * | -160M -171M | Net income 2025 * | -165M -176M | EV / Sales 2024 * | 306 x |
Net cash position 2024 * | 87.4M 93.18M | Net cash position 2025 * | 44.68M 47.63M | EV / Sales 2025 * | 399 x |
P/E ratio 2024 * |
-5.52
x | P/E ratio 2025 * |
-5.2
x | Employees | 61 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.25% |
Latest transcript on Abivax
1 day | -0.71% | ||
1 week | +1.74% | ||
Current month | +4.63% | ||
1 month | +8.35% | ||
3 months | +36.65% | ||
6 months | +19.02% | ||
Current year | +42.77% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 66 | 23-05-04 | |
Didier Blondel
DFI | Director of Finance/CFO | - | 17-01-01 |
Sheldon Sloan
CTO | Chief Tech/Sci/R&D Officer | - | 23-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 65 | 13-12-03 | |
Kinam Hong
BRD | Director/Board Member | - | - |
Troy Ignelzi
BRD | Director/Board Member | 56 | 23-07-10 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 14 | -0.85% | 3 871 |
24-04-18 | 14.12 | -0.28% | 16,031 |
24-04-17 | 14.16 | +1.14% | 35,372 |
24-04-16 | 14 | +0.14% | 26,377 |
24-04-15 | 13.98 | +1.45% | 25,188 |
Real-time Euronext Paris, April 19, 2024 at 05:53 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+42.77% | 947M | |
-1.82% | 41.35B | |
+42.38% | 40.38B | |
+2.56% | 39.05B | |
-12.11% | 26.67B | |
+3.09% | 24.07B | |
-24.16% | 18.36B | |
+22.12% | 11.6B | |
-3.74% | 11.68B | |
+7.75% | 11.15B |
- Stock Market
- Equities
- ABVX Stock